Galapagos

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public

Established: 1999-01-01

Employees: 1.1K

Market Cap: $1.9B

Website: http://www.glpg.com

Introduction: Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in M...

Clinical Trials

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: GLPG0634

First Posted Date: 2014-03-11

Last Posted Date: 2014-07-22

Lead Sponsor: Galapagos NV

Target Recruit Count: 24

Registration Number: NCT02084199

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Filgotinib

First Posted Date: 2014-02-19

Last Posted Date: 2024-06-04

Lead Sponsor: Galapagos NV

Target Recruit Count: 739

Registration Number: NCT02065700

Locations: 🇺🇦
Municipal Non-profit Enterprise Consultative and Diagnostic Center of Pechersk District of Kiev city, Kyiv, Ukraine
🇺🇦
L.T. Malaya Therapy Institute of National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine
🇺🇦
Kherson City Clinical Hospital N. A. Afanasii and Olga Tropin, Kherson, Ukraine

and more 108 locations

Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: Placebo
Drug: GLPG0634

First Posted Date: 2014-01-29

Last Posted Date: 2016-02-23

Lead Sponsor: Galapagos NV

Target Recruit Count: 175

Registration Number: NCT02048618

Locations: 🇭🇺
Szent Margit Hospital, Budapest, Hungary
🇫🇷
Hospital Gabriel Montpied, Clermont-Ferrand, France
🇩🇪
University Hospital Jena, Jena, Germany

and more 59 locations

Oral Bioavailability of Two Solid Formulations of GLPG0634

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 200 mg GLPG0634 as capsules, fasted
Drug: 200 mg GLPG0634 as tablets, fasted
Drug: 200 mg GLPG0634 as tablets, fed

First Posted Date: 2013-08-05

Last Posted Date: 2013-09-17

Lead Sponsor: Galapagos NV

Target Recruit Count: 12

Registration Number: NCT01915667

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: GLPG0634
Drug: Placebo

First Posted Date: 2013-07-10

Last Posted Date: 2020-12-16

Lead Sponsor: Galapagos NV

Target Recruit Count: 287

Registration Number: NCT01894516

Locations: 🇺🇸
Little Rock Diagnostic Clinic, Little Rock, Arkansas, United States
🇺🇸
Arizona Arthritis & Rheumatology Research PLLC, Mesa, Arizona, United States
🇺🇸
C.V. Mehta MD Medical Corp., Hemet, California, United States

and more 79 locations

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: GLPG0634
Drug: Placebo

First Posted Date: 2013-06-28

Last Posted Date: 2020-11-17

Lead Sponsor: Galapagos NV

Target Recruit Count: 599

Registration Number: NCT01888874

Locations: 🇧🇬
MHAT Ruse AD, Ruse, Bulgaria
🇩🇪
Rheumazentrum Ruhrgebiet, Herne, Germany
🇺🇸
The Arthritis Center, Springfield, Illinois, United States

and more 139 locations

First-in-Human Single and Multiple Dose of GLPG1205

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG1205 single ascending doses, oral suspension
Drug: Placebo single ascending doses, oral suspension
Drug: GLPG1205, multiple ascending doses, oral suspension
Drug: Placebo, multiple ascending doses, oral suspension

First Posted Date: 2013-06-26

Last Posted Date: 2013-10-16

Lead Sponsor: Galapagos NV

Target Recruit Count: 40

Registration Number: NCT01887106

Locations: 🇧🇪
SGS LSS Clinical Pharmacology Unit Antwerp, Antwerp, Belgium

Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: GLPG0974
Drug: Placebo

First Posted Date: 2013-04-11

Last Posted Date: 2014-04-25

Lead Sponsor: Galapagos NV

Target Recruit Count: 45

Registration Number: NCT01829321

Locations: 🇱🇻
Rīgas slimnīca Bikor Holim, Riga, Latvia
🇨🇿
Fakulní nemocnice Olomouc, Olomouc, Czech Republic
🇱🇻
Latvijas Jūras Medicīnas Centrs, Riga, Latvia

and more 13 locations

Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 100 mg dose of [14C] GLPG0634

First Posted Date: 2013-03-29

Last Posted Date: 2013-05-07

Lead Sponsor: Galapagos NV

Target Recruit Count: 6

Registration Number: NCT01820806

Locations: 🇬🇧
Quotient Clinical, Nottingham, United Kingdom

A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG0634
Drug: Midazolam

First Posted Date: 2013-02-26

Last Posted Date: 2013-05-07

Lead Sponsor: Galapagos NV

Target Recruit Count: 20

Registration Number: NCT01798979

Locations: 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy